Check out Intouch EVP David Windhausen's thoughts on the potential of voice technology in pharma and healthcare for the Forbes Technology Council.
It's still early days for artificial intelligence (AI) in the pharma and healthcare space. So much depends on navigating the regulatory environment, yet great strides are being made ... they're just not quite as sexy as, say, a chatbot or what IBM once promised Watson would be. To learn more
Google recently noted that four out of five people "say digital video helps them learn new things," and for understanding things like artificial intelligence (AI) and where it sits on the Gartner Hype Cycle, video is the go-to teaching format. The Gartner Hype Cycle is published annually, and the
This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.
Harmonious collaboration produces the best work from your agencies, but getting everyone to be on the same page can be a challenge. How do you ensure that everyone’s doing their part? How can you work effectively and efficiently when there are multiple players, multiple meetings and – more than likely
The MM&M Awards shortlist is out, and Intouch has been nominated for 11 awards, including Agency of the Year!
Last fall, we published a POV called “Should Pharma Care About California’s New Data Privacy Law?” Since then, we’ve been monitoring the legislative process and the discussions and reactions of opinion leaders. This updated POV provides the latest thinking on this law and its implications for pharma marketers.
Data science: a term that always sounds cutting-edge. While discussions of personalized medicine and the related science of gene therapy and similar advances become more science than science fiction, pharma marketing is beginning to step into the individualized, independent experience economy, as well. What is the experience economy? It’s not
On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures. What happens next?
On Monday, June 24, 2019, the Food and Drug Administration finalized its guidance on electronic submissions of promotional materials. This Intouch POV provides an overview of the most significant aspects of the guidance, including the most important changes from the 2015 draft version.
